Abstract
Patients with inflammatory bowel disease (IBD) are recommended to receive vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), regardless of their immunosuppression status. Immunosuppressive medications represent a mainstay of therapy in moderate to severe IBD; however, their impact on the SARS-CoV-2 vaccine response remains unclear. Studies thus far have shown that patients with IBD on various therapies had detectable antibody responses after standard vaccinations. 1-5 To date, one study has examined the kinetics of antibody response at 3 months after vaccination in patients with IBD, but data beyond this time point are not yet available. 6 The aim of this study was to assess anti-spike antibody response 6 months after completion of standard SARS-CoV-2 vaccination in patients with IBD. Secondarily, we observed antibody kinetics over 6 months in a subset of patients post-vaccination.
【초록키워드】 SARS-CoV-2, coronavirus, vaccination, therapy, Antibody Response, Immunosuppression, severe acute respiratory syndrome Coronavirus, SARS-CoV-2 vaccine, Inflammatory bowel disease, Kinetics, vaccine response, antibody kinetics, Patient, medication, moderate, SARS-CoV-2 vaccination, anti-spike antibody, IBD, Vaccinations, moderate to severe, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, anti-spike antibody response, completion, immunosuppressive medications, shown, examined, detectable, subset, receive, the SARS-CoV-2, 【제목키워드】 SARS-CoV-2, mRNA, response, Month,